SCHEMBL3582641

SCHEMBL3582641

Cc1c(N2CCOCC2)ccc2[nH]c(-c3[c]cn(C(N)=O)n3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.42
CXCR3 P49682 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FGFR1 P11362 1/20 0.36
BRD4 O60885 2/20 0.35
SIRT2 Q8IXJ6 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
HTT P42858 3/20 0.32
GRIN2B Q13224 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KDM4E B2RXH2 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
CLK2 P49760 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930935 0.77 FGFR1 (0.40) PARP1NPC1RAB9ASMN1; SMN2FGFR1
SCHEMBL5547011 0.73 ATR (0.44) FGFR1JAK2
SCHEMBL546668 0.72 PARP1 (0.45) PARP1NPC1RAB9AFGFR1HSD17B10
SCHEMBL5952191 0.68 HPSE (0.43) NPC1RAB9AFGFR1HSD17B10KDM4E
SCHEMBL2446340 0.67 SMN1; SMN2 (0.41) PARP1NPC1RAB9ASMN1; SMN2BRD4
SCHEMBL5953399 0.65 PTGDR2 (0.43) CXCR3
SCHEMBL28516755 0.59 RAB9A (0.45) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL1199030 0.58 L3MBTL1 (0.51) SMN1; SMN2HTTLMNAPOLBHSD17B10
SCHEMBL20765122 0.56 ADORA2A (0.45) SMN1; SMN2PIK3CDPIK3CGJAK2
SCHEMBL16039735 0.56 ALDH1A1 (0.48) RAB9ASMN1; SMN2HTTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399442-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2013-03-19 US disclosed
US-20100004232-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (UK) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004232-A1 Pharmaceutical Compounds ERBB3, ABL1, RET PARP1 4774/4885CXCR3 664/4885NPC1 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.